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Objective: To identify risk factors and stratify their effect of compromising 3-year survival in patients treated for
asymptomatic carotid disease based upon recently updated guidelines from the Society for Vascular Surgery.
Methods: Outcomes of 506 patients who underwent carotid intervention for asymptomatic carotid disease (1999-2008)
were analyzed. Hospital computerized medical records were reviewed. When local records were sparse, Social Security
Death Index was queried to conﬁrm mortality. Following multivariable Cox regression analysis, a score was assigned
based on the calculated hazard ratio (HR) in the following fashion: HR 1.5-1.9[ 1 point; HR 2.0-3.0[ 2 points; and
HR >3[ 3 points. The sum of those points comprised the ﬁnal score for each patient. Kaplan-Meier analyses were then
performed to delineate survival differences.
Results: Seventy patients (13.83%) did not survive beyond 3 years after the procedure. Age >80 years (HR, 1.79; P[ .05;
score 1), diabetes mellitus (HR, 1.99; P < .05; score 1), coronary artery intervention (HR, 2.03; P < .01; score 2), severe
chronic kidney disease deﬁned as glomerular ﬁltration rate <30 and not on dialysis (HR, 2.46; P[ .03; score 2), dialysis
patients (HR, 5.67; P [ .001; score 3), and chronic obstructive pulmonary disease (HR, 3.53; P < .001; score 3)
negatively inﬂuenced 3-year survival. Patients with score #2 experienced 3-year mortality of 6.0%, whereas score >2 was
associated with 31.6% 3-year mortality (HR, 6.10; P < .001). The score value was not associated with the stroke rate at any
time point. The resultant score was validated in a separate population of patients with symptomatic carotid disease.
Conclusions: This easy predictive score underscores the association of medical risk factors with decreased 3-year survival.
This ﬁnding may impact future clinical decisions for management of asymptomatic carotid disease. (J Vasc Surg
2013;57:1576-80.)Recently updated guidelines from the Society for
Vascular Surgery established that patients with asymptom-
atic carotid stenosis who are at high risk for intervention or
have less than 3 years life expectancy should be considered
to receive medical management as the ﬁrst-line therapy.1
Other authors have also recommended no intervention in
patients with estimated life expectancy of less than 5 years.2
However, predicting survival in vascular patients can be
difﬁcult, considering that these patients may already harbor
signiﬁcant coronary artery disease (CAD) and other co-
morbidities that frequently decrease life expectancy when
compared with age-matched, healthy individuals. The aim
of this work was to develop a risk scoring system by iden-
tifying medical risk factors that may have a signiﬁcant
impact upon 3-year survival among patients receiving inter-
vention for asymptomatic carotid stenosis.
METHODS
A prospectively maintained vascular database was
queried for patients undergoing carotid endarterectomythe University of Alabama at Birmingham.
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6or carotid angioplasty and stenting for asymptomatic
carotid stenosis at the University of Alabama at Birming-
ham from January 1999 through December 2008. Asymp-
tomatic carotid stenosis was deﬁned as internal carotid
artery stenosis of 60% or more in a patient with absence
of ipsilateral neurological symptoms for at least 6 months
before the procedure. The degree of carotid stenosis was
determined primarily by ultrasound and selectively con-
ﬁrmed by arteriogram, computerized tomography angio-
gram, or by magnetic resonance imaging based upon
surgeon preference. Ofﬁce records were used primarily,
but hospital computerized records and phone records
were used as needed. Social Security Death Index (SSDI)
was consulted for all patients lost to follow up for more
than 12 months. Demographics and clinical data were
collected. The primary endpoint was survival at 3 years
after carotid interventions, and secondary endpoints were
stroke at 30 days, 1 year, and 3 years, and mortality at
30 days and 1 year. Patients undergoing combined coro-
nary artery bypass graft (CABG) and carotid intervention
and those with incomplete medical information were
excluded from the analysis. Exposure variables were
medical conditions occurring at the time of the carotid
intervention and categorized as follows: race, hypertension,
hyperlipidemia, current smokers, octogenarians, diabetes
mellitus (DM), CAD, chronic kidney disease (CKD), and
chronic obstructive pulmonary disease (COPD). Hyper-
tension included patients with established diagnosis at the
time of carotid intervention. DM was deﬁned as documen-
tation of diabetes in the medical record and the conﬁrmed
use of oral hypoglycemic medications or insulin. CAD
Table I. Demographics in 506 patients
Variables mean (6SD) or No. (%)
All patients
(n ¼ 506) % or SD
Age, years 69 69
Age $80 years 70 14
Female 191 38
Non-whites 39 8
Current smokers 119 24
Coronary intervention 214 42
DM 150 30
Hypertension 363 72
Hyperlipidemia 268 53
COPD 49 10
GFR >60 319 63
GFR 30-59 155 31
GFR #30; no dialysis 22 4
Dialysis 10 2
COPD, Chronic obstructive pulmonary disease; DM, diabetes mellitus;
GFR, glomerular ﬁltration rate; SD, standard deviation.
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neous coronary intervention. CKD was based on glomer-
ular ﬁltration rate (GFR; mL/min/1.75 m2) and
adjusted for race and gender using the isotope dilution
mass spectrometry-traceable Modiﬁcation of Diet in Renal
Disease Study equation according to the National Kidney
Foundation guidelines3 and was divided as follows: (a)
normal or mild CKD: GFR $60; (b) moderate CKD:
GFR 30-59; (c) severe CKD: GFR <30 no dialysis; and
(d) dialysis patients. COPD included any patient with
established diagnosis at the time of carotid intervention.
Using multivariate Cox proportional-hazards regression
analysis, a 3-year mortality hazard ratio (HR) for each
medical condition was obtained, and a value was assigned
based on the calculated HR in the following fashion: HR
1.5-1.9 ¼ 1 point; HR 2.0-3.0 ¼ 2 points; and HR >3 ¼
3 points. Only HRs$1.5 with a P value #.05 were consid-
ered. The sum of those points comprised the ﬁnal score for
each patient. Subsequently, Kaplan-Meier analysis was used
to delineate survival differences. Finally, the resultant score
was applied in a different population of 352 patients with
symptomatic carotid disease for validation.
Statistical analysis. The inﬂuence of comorbidities on
long-term survival was evaluated using multivariate and
univariate Cox proportional-hazards regression analysis.
The following variables were included in the model: age,
race, hypertension, hyperlipidemia, COPD, DM, CAD,
CKD, and smoking. Long-term survival was determined
with Kaplan-Meier life table and log-rank test.
RESULTS
A total of 582 carotid revascularizations for asymptom-
atic carotid stenosis were performed in 552 patients during
the 10-year period. For patients with two procedures, only
the second intervention was considered for analysis. After
exclusion of duplicates (33), patients with combined
CABG and carotid intervention (n ¼ 13), and incomplete
information (n ¼ 30), a total of 506 carotid interventions
(427 carotid endarterectomy and 79 carotid angioplasty
and stenting) in 506 patients comprise the basis of this
report. Carotid stenosis was graded as 60% to 79% in
18% of patients and greater than 80% in 82% of patients.
Baseline characteristics of the 506 patients are depicted in
Table I. Seventy patients (13.83%) did not survive beyond
3 years post-procedure. Eight patients were lost to follow
up and not found dead through the SSDI during the ﬁrst
3 years after intervention. After adjusting for confounders,
age >80 years (HR, 1.79; score 1), DM (HR, 1.99; score
1), coronary artery intervention (HR, 2.03; score 2), severe
CKD deﬁned as GFR <30, no dialysis (HR, 2.46; score 2),
dialysis patients (HR, 5.67; score 3), and COPD (HR,
3.53; score 3) negatively inﬂuenced 3-year survival
(Table II). The other comorbidities analyzed did not
have impact in 3-year mortality (female HR, 1.10; P ¼
.71; current smokers HR, 1.19; P ¼ .51; hypertension
HR, 1.19; P ¼ .55; hyperlipidemia HR, 0.83; P ¼ .49).
Patients with scores of 0 (n ¼ 172), 1 (n ¼ 80), and 2
(n ¼ 99) had a 3-year mortality of 5.84%, 6.25%, and6.06%, respectively. On the other hand, patients with
scores of 3 (n ¼ 89), 4 (n ¼ 19), 5 (n ¼ 36), and 6
(n ¼ 11) had a 3-year mortality of 24.71%, 42.1%,
41.6%, and 33.3% respectively. Once patients reached
a score greater than 2, the 3-year mortality increased
considerably, thus we chose to break the scores into two
groups (#2 and >2).
Sensitivity, speciﬁcity, positive predictive value, and
negative predictive value for 3-year survival by score #2
were 75.68% (95% conﬁdence interval [CI], 71.3%-
79.5%), 70% (95% CI, 57.7%-80.0%), 94.01% (95% CI,
90.8%-96.1%), and 31.61% (95% CI, 24.5%-39.6%)
Univariate analysis demonstrated that cumulative score
#2 was related to a 3-year mortality of 6.0% (95% CI,
3.8%-9.5%), whereas score >2 had a 3-year mortality of
31.6% (95% CI, 26.6%-34.8%; P < .001; Fig 1, A).
When risk score >2 was compared with risk score #2 in
Kaplan-Meier survival analysis, it was signiﬁcantly associ-
ated with 3-year mortality (HR, 6.10; 95% CI, 3.65-
10.17; P < .001; Fig 2). The survival rate did not change
over the time of the study (Fig 3). Thirty-day mortality was
also greater in patients with score >2, although it did not
reach statistical signiﬁcance (0.6% and 1.9%; HR, 3.42;
95% CI, 0.57-20.44; P ¼ .17). Non-white patients repre-
sented 8% of the population; however, 3-year mortality
was similar to the white patients (score #2 ¼ 7.4% and
score >2 ¼ 25%). Stroke rate was not inﬂuenced by scores
at 30 days, 1, or 3 years (score #2 ¼ 2.3%, 2.6%, and 2.8%;
score >2 ¼ 1.9%, 2.6%, and 3.9%; P ¼NS; Table III). Vali-
dation of the score in a population of 352 patients with
symptomatic carotid disease resulted in a 3-year all-cause
mortality of 7.57% (95% CI, 4.9%-11.5%) and 32.95%
(95% CI, 24.0%-43.3%) for score #2 and >2, respectively
(P < .001; Fig 1, B). The sensitivity, speciﬁcity, positive
predictive value, and negative predictive value for 3-year
survival by score #2 in the validation sample were
78.21% (95% CI, 73.05%-82.64%), 63.26% (95% CI,
48.23%-76.20%), 92.94% (95% CI, 88.88%-95.64%), and
31.9% (95% CI, 23.06%-42.3%).
Table II. Predictors of 3-year all-cause mortality
3-year all-cause
mortality, No. (%)
Adjusted HR
(95% CI) P value Score
Octogenarians
No (n ¼ 436) 56 (12.8) 1.79 (0.98-3.29) .05 1
Yes (n ¼ 70) 14 (20)
DM
No (n ¼ 356) 36 (10.1) 1.99 (1.22-3.26) <.05 1
Yes (n ¼ 150) 34 (22.7)
Coronary intervention
No (n ¼ 292) 26 (8.9) 2.03 (1.21-3.40) <.01 2
Yes (n ¼ 214) 44 (20.6)
COPD
No (n ¼ 457) 53 (11.6) 3. 53 (2.01-6.21) <.001 3
Yes (n ¼ 49) 17 (34.7)
CKD
GFR >60 (n ¼ 319) 34 (10.7) Ref
GFR 30-59 (n ¼ 155) 24 (15.5) 1.20 (0.70-2.07) .49 0
GFR <30 (n ¼ 22) 8 (36.4) 2.46 (1.06-5.70) .03 2
Dialysis (n ¼ 10) 4 (40) 5.67 (1.94-16.58) .001 3
CI, Conﬁdence interval; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; GFR, glomerular ﬁltration rate;
HR, hazard ratio.
A
B
Fig 1. Three-year mortality in 506 patients with asymptomatic
carotid disease (A) and validation of score system in a different
population of 352 patients with symptomatic carotid disease (B).
Fig 2. Kaplan-Meier plots for 3-year all-cause mortality for carotid
stenosis patients with scores $2 and scores <2. CI, Conﬁdence
interval; HR, hazard ratio.
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Optimal treatment for asymptomatic carotid stenosis is
a matter of continuous and growing debate.4-6 Such debate
centers upon the overall impact of concurrent medical
conditions, the suitability of patients to undergo carotidintervention, and their predicted lifespan to receive the
beneﬁt of a particular intervention. Advances in medical
therapy to include the widespread use of B-blockade, anti-
platelet regimens, and statins have likely improved the
modern deﬁnition of “best medical therapy.”While current
research aims to better identify subgroups at higher risk for
stroke7,8; appropriate patient selection continues to be an
important factor for a prophylactic carotid intervention to
be successful. In this report, we analyzed the impact on
3-year post intervention mortality of comorbidities
commonly seen in our population of patients with vascular
disease. After our initial analysis of risk factors, we devel-
oped a predictive scoring system to better estimate the
minimum life expectancy recently recommended by the
Fig 3. Three-year survival based on year of study entry.
Table III. Risk score and outcomes
Outcomes
Events, No. (%)
Absolute risk
differencea
HRb
(95% CI) P value
Score #2
(n ¼ 351)
Score >2
(n ¼ 155)
Stroke
Stroke e 30 days 8 (2.3) 3 (1.9) 0.4% 0.86 (0.22-3.24) .823
Stroke e 1 year 9 (2.6) 4 (2.6) 0.0% 1.08 (0.33-3.52) .893
Stroke e 3 years 10 (2.8) 6 (3.9) þ1.1% 1.76 (0.63-4.85) .274
All-cause mortality
All-cause mortality e 30 days 2 (0.6) 3 (1.9) þ1.3% 3.42 (0.57-20.44) .178
All-cause mortality e 1 year 7 (2.0) 16 (10.3) þ8.3% 5.41 (2.23-13.16) <.001
All-cause mortality e 3 years 21 (6.0) 49 (31.6) þ25.6% 6.10 (3.65-10.17) <.001
CI, Conﬁdence interval; HR, hazard ratio.
aAbsolute risk differences were calculated by subtracting percent events in patients with score #2 from those with score >2.
bHRs comparing patients with score #2 with those with score >2.
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ical decision for management of asymptomatic carotid
disease (ie, intervention versus medical therapy), whereas
the beneﬁt of revascularization will not become evident
until 2 years or more after intervention.9 With an annual
rate of stroke in medically treated patients of 2%, the antic-
ipated 3-year mortality for carotid revascularization should
ideally not exceed the 6% stroke risk at the same time
interval (ie, at least 94% 3-year survival). In accordance
with other reports,10,11 COPD and end-stage renal disease
are related with poor survival (3 points each in the
proposed score system), and therefore medical therapy
could represent the best ﬁrst-line approach. Revasculariza-
tion might then be reserved for those patients with docu-
mented progression of their disease or those who develop
symptoms. On the other hand, isolated octogenarians,
DM, severe CKD (GFR <30 no dialysis), and CAD
(1 and 2 points) should not be an impediment for an indi-
cated prophylactic carotid intervention plus medical treat-
ment, particularly if their medical disease is well
managed. For example, the simultaneous presence ofa CAD intervention and DM or octogenarians in a patient
suggests the associated risks of mortality act synergistically
to outweigh the risk of stroke from the carotid lesion
alone.12-14 In this study, the 3-year mortality of patients
with only CAD (score 2) was 5.61%, only DM (score 1)
was 7.84% and octogenarians without any other comorbid-
ity (score 1) was 2.63%. However, the 3-year mortality of
octogenarians plus CAD (score 3) was 27.77% and
CAD þ DM (score 3) was 25.92%. Octogenarians plus
DM had a 3-year mortality of 0%. These results are sup-
ported by previous reports that show the negative impact
on survival with cumulative comorbidities.15-17
Historically, there have been cyclical rates of carotid
endarterectomy depending upon the trend of published
trials.18 In the 90s, after those rates rose again, the beneﬁt
of surgery in the asymptomatic patient was established;
however, it was also stated that intervention did not appear
to be cost-effective in patients with a very low stroke risk
without surgery.19 Perhaps a better algorithm decision
for therapy would be directed toward preoperative and
postoperative optimization of treatable medical illnesses.
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viewed as an investment in time. Aggressive treatment of
associated comorbidities in these patients could allow
them to live long enough to beneﬁt from the increased
reduction in stroke risk seen with revascularization if used
with medical treatment. This beneﬁt in stroke reduction
can be further enhanced by accurate identiﬁcation of
high-risk patients who will beneﬁt from carotid interven-
tion. As shown here, acceptable stroke reduction can be
achieved after carotid intervention, and even the higher
risk group could successfully undergo carotid revasculariza-
tion with a low stroke rate; however, more than 30% of
high-risk patients did not survive the recommended 3 years
to beneﬁt from stroke reduction.
Our conclusions may be limited due to some methods
of the study. While the patients are gathered prospectively,
some of the risk factors are gathered retrospectively. Specif-
ically, we did not have detailed spirometry information to
document COPD but used prior diagnoses from the
medical chart or the presence of COPD treatment with
medication. Additionally, our single institution had only
a limited number of patients, but this may represent the
treatment volumes of many urban centers. Finally,
although the results obtained with this score were repli-
cated in a different patient population with carotid stenosis,
that was a small sample and there may be more validity to
apply this model in a prospective way to patients with
asymptomatic carotid stenosis.
CONCLUSIONS
Medical comorbidities have a signiﬁcant association
with survival after intervention for carotid artery disease.
In our population, the comorbidities of age, diabetes,
pulmonary, cardiac, or renal disease did not singularly
have an impact on early mortality. However, a simple
predictive score system that factors the effects of multiple
comorbidities may identify patients who require intensive
medical therapy to maximize their survival after carotid
intervention.
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